Christopher Raymond
Stock Analyst at Piper Sandler
(3.34)
# 1,014
Out of 5,090 analysts
138
Total ratings
51.33%
Success rate
1.94%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $9 → $10 | $5.98 | +67.22% | 10 | Nov 4, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $5.05 | +157.43% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $8.65 | +235.26% | 2 | Oct 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $226.08 | +25.62% | 13 | Oct 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $114.51 | -38.87% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $181.30 | -36.57% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.42 | +533.80% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $53.40 | +135.96% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.32 | +20.48% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $455.48 | +17.02% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $718.36 | +41.02% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $36.38 | +284.83% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $80.38 | -10.43% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $2.92 | +345.21% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.75 | +1,204.35% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.55 | +695.81% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.70 | +1,335.34% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $21.50 | +53.49% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $38.77 | -43.26% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.54 | +159.74% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $329.89 | -12.70% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.73 | +47.85% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $48.14 | -41.84% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $109.60 | -63.50% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.77 | +1,459.79% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.07 | +4,537.68% | 2 | Mar 13, 2020 |
Ardelyx
Nov 4, 2025
Maintains: Neutral
Price Target: $9 → $10
Current: $5.98
Upside: +67.22%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $5.05
Upside: +157.43%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $8.65
Upside: +235.26%
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $226.08
Upside: +25.62%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $114.51
Upside: -38.87%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $181.30
Upside: -36.57%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.42
Upside: +533.80%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.40
Upside: +135.96%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.32
Upside: +20.48%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $455.48
Upside: +17.02%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $718.36
Upside: +41.02%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $36.38
Upside: +284.83%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $80.38
Upside: -10.43%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $2.92
Upside: +345.21%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.75
Upside: +1,204.35%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.55
Upside: +695.81%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.70
Upside: +1,335.34%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $21.50
Upside: +53.49%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $38.77
Upside: -43.26%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.54
Upside: +159.74%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $329.89
Upside: -12.70%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.73
Upside: +47.85%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $48.14
Upside: -41.84%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $109.60
Upside: -63.50%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.77
Upside: +1,459.79%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.07
Upside: +4,537.68%